Therefore, the current study was designed to detect this FANCD2 mutant in AP-CML (early progression phase) and to clinically validate its potential as a novel molecular biomarker of early CML progression from CP to AP. The gene discussed is FANCD2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.